Can ticagrelor (Brilinta) be prescribed together with enoxaparin (Lovenox)?

Yes, Brilinta (ticagrelor) can be prescribed together with Lovenox (enoxaparin)

This combination is explicitly supported by major cardiovascular guidelines and is commonly used in acute coronary syndrome (ACS) management, with no clinically significant drug interactions between these agents.

Evidence Supporting Concurrent Use

The 2014 AHA/ACC guidelines for non-ST-elevation ACS specifically recommend both agents as part of standard treatment protocols 1, 2. The guidelines indicate:

• Enoxaparin dosing: 1 mg/kg subcutaneously every 12 hours (reduced to once daily if creatinine clearance <30 mL/min), continued for the duration of hospitalization or until PCI is performed 1
• Ticagrelor use: Recommended as a Class IIa indication in preference to clopidogrel for P2Y12 treatment in NSTE-ACS patients undergoing early invasive or ischemia-guided strategies 1

The 2025 ACC/AHA guidelines for ACS management continue to support ticagrelor as a Class I recommendation for patients with ACS, including those receiving anticoagulation 3.

Pharmacological Compatibility

A dedicated pharmacokinetic study demonstrated no clinically significant drug-drug interactions between ticagrelor and enoxaparin 4. This randomized crossover trial in healthy subjects found:

• Co-administration with enoxaparin had no significant effect on ticagrelor pharmacokinetics
• Only a marginal reduction in platelet inhibition (AUEC decreased by 2.9%) when combined with enoxaparin—clinically insignificant
• Ticagrelor had no clinically significant effects on enoxaparin's anticoagulant activity as measured by anti-factor Xa levels
• Both drugs were well tolerated together with no significant bleeding or serious adverse events 4

Clinical Context and Practical Considerations

When This Combination is Used:

• Acute coronary syndromes (STEMI and NSTE-ACS) requiring both antiplatelet and anticoagulant therapy 1, 2, 5
• Patients managed with early invasive strategy or ischemia-guided approach
• Bridge therapy until coronary anatomy is defined and revascularization strategy determined

Important Dosing Details:

• Ticagrelor: 180 mg loading dose, then 90 mg twice daily 6
• Aspirin with ticagrelor: Should be limited to 75-100 mg daily maintenance dose (NOT higher doses) 1, 6
• Enoxaparin: Standard ACS dosing as above, with renal adjustment 1

Bleeding Risk Management:

While both agents increase bleeding risk individually, their combination is standard practice in ACS. The key is appropriate patient selection and monitoring 6:

• Avoid in patients with active pathological bleeding or history of intracranial hemorrhage 6
• Consider radial access for coronary procedures to minimize bleeding 7
• Monitor for bleeding complications, particularly in elderly patients or those with renal impairment
• Recent real-world data suggests enoxaparin combined with ticagrelor shows hemorrhagic signals, but this is expected and manageable with proper monitoring 8

Duration Considerations:

• Enoxaparin is typically used during the acute hospitalization phase or until PCI is performed 1, 2
• Ticagrelor continues long-term (at least 12 months post-ACS) 3, 6
• This combination is not intended for prolonged concurrent use—enoxaparin is discontinued once the acute phase resolves

Common Pitfalls to Avoid:

1. Do NOT use high-dose aspirin (>100 mg) with ticagrelor—this reduces ticagrelor's effectiveness 6
2. Do NOT combine ticagrelor with other oral P2Y12 inhibitors (clopidogrel, prasugrel) 6
3. Adjust enoxaparin for renal dysfunction to prevent excessive anticoagulation 1
4. Avoid in patients requiring long-term oral anticoagulation unless carefully managed with specific protocols for triple therapy 9, 10, 11

The combination of Brilinta and Lovenox is guideline-supported, pharmacologically compatible, and routinely used in clinical practice for ACS management.